MGF (Mechano Growth Factor)
Also known as: Mechano Growth Factor, IGF-1Ec, IGF-1 Ec splice variant, MGF E-peptide
Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
MGF is the IGF-1Ec splice variant of IGF-1 that muscle produces locally after mechanical loading/damage. Its unique 24-amino-acid E-domain (the "MGF E-peptide") is thought to activate quiescent satellite cells and drive myoblast proliferation, a plausible route to hypertrophy and repair. It is prohibited by WADA under S2 as a growth factor. It is rated 4 rather than higher because, unlike IGF-1 LR3, the injectable-MGF hypertrophy story is largely community practice: the E-peptide's receptor was never definitively identified, native MGF lasts only minutes, and at least one study found synthetic MGF peptide had no apparent effect on human myoblasts/muscle stem cells. It is an anabolic growth factor with real mechanistic promise but thin human proof.
Overview
A locally-acting splice variant of IGF-1 (IGF-1Ec) that skeletal muscle produces in response to mechanical strain and damage, hence "Mechano Growth Factor." It consists of the mature IGF-1 domain plus a unique 24-amino-acid E-domain; the cleaved E-peptide is the biologically distinctive part, believed to activate satellite (muscle stem) cells that donate new nuclei to repairing and growing fibers. Native MGF acts locally for only minutes, so a PEGylated version (PEG-MGF) was created to extend its half-life for systemic use.
Purpose & Use Cases
Satellite Cell Activation
The E-peptide is proposed to wake up quiescent muscle stem cells and drive their proliferation, expanding the pool available to repair and grow fibers.
Muscle Repair & Recovery
Community use targets faster recovery from training and injury by amplifying the local repair response that mechanical damage normally triggers.
Local Hypertrophy (Native MGF)
Native MGF's minutes-long half-life means it is injected into a specific muscle post-workout for a localized effect, similar in spirit to IGF-1 DES site enhancement.
Systemic Effect (PEG-MGF)
The PEGylated form circulates for days, so it is dosed less frequently for a body-wide rather than site-specific effect.
Benefits
- Proposed satellite-cell activation (a route to new myonuclei, not just bigger fibers)
- May accelerate recovery from training and muscle damage
- Native MGF allows targeted, post-workout localized use
- PEG-MGF extends half-life to days for systemic dosing
- Does not suppress testosterone, no PCT required
- Less systemic hypoglycemia/organ-growth signalling than IGF-1 LR3 (E-peptide binds IGF-1R weakly)
Good to Know
It is an IGF-1 splice variant, not a separate hormone
MGF = IGF-1Ec: the same IGF-1 gene, spliced to include a unique 24-amino-acid E-domain. The bodybuilding "MGF" of interest is usually that cleaved E-peptide, which is thought to act on satellite cells independently of the classical IGF-1 receptor. It is a cousin of IGF-1 LR3/DES, not an unrelated compound.
Native vs PEG-MGF changes how you use it
Native MGF survives only minutes, so it is injected locally right after training for a site-specific effect. PEG-MGF is PEGylated to last days, so it is dosed a couple of times weekly for a systemic effect and is not tied to the workout window. Buying the wrong one for your protocol is a common mistake.
Evidence is thinner than the hype
Goldspink's group (e.g. Kandalla 2011) showed the E-peptide activates human muscle progenitor cells in culture, but the responsible receptor was never nailed down, and Fornaro et al. (2014) found synthetic MGF peptide had no apparent effect on myoblasts or primary muscle stem cells. There are essentially no human hypertrophy trials of injected MGF. Its physique use is community practice extrapolated from cell/animal work.
Not DHT-related and needs no AI
MGF is a growth factor, not an androgen. It does not aromatize, does not convert to DHT, and has no bearing on hair loss or estrogen. No AI and no finasteride considerations apply.
WADA-banned even though it is "just a peptide"
MGF and PEG-MGF are prohibited at all times under S2 as growth factors. Tested athletes should treat it exactly like IGF-1. It is not a grey-area recovery aid in a doping-control sense.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 100 – 200 mcg/day |
| Intermediate | 200 – 300 mcg/day |
| Advanced | 300 – 400 mcg/day |
There is no validated human dose. These ranges reflect community protocols, not clinical data. Native MGF is timed to the post-workout window and injected into or near the trained muscle because it clears within minutes; PEG-MGF is dosed a couple of times weekly for a systemic effect. A common sequencing idea is to run PEG-MGF after a GH/IGF-1 pulse (e.g. on rest days or later post-workout) rather than at the same time, on the theory that IGF-1 handles differentiation once MGF has driven proliferation. Reconstitute with bacteriostatic water and refrigerate.
Native MGF is rapidly metabolised in vivo (on the order of minutes) and acts locally; the ~2-3 day figure for PEG-MGF is a community/vendor estimate rather than a published pharmacokinetic study.
Side Effects
Injection Site Reaction
commonRedness, itching, or a mild lump at the injection site, more noticeable with frequent local (native MGF) injections.
Rotate sites; use proper sterile technique.
Flushing / Warmth
uncommonTransient facial flushing or a feeling of warmth after PEG-MGF injection.
Usually settles on its own; lower the dose if bothersome.
Theoretical Growth-Promoting Risk
rareAs a growth factor that stimulates cell proliferation, chronic high-dose use carries the same theoretical concern as other IGF-1-family peptides about promoting growth of existing/dormant abnormal cells. Unproven for MGF specifically, but mechanistically shared with IGF-1.
Avoid with a personal/family history of cancer. Keep doses and cycle lengths conservative.
Sourcing / Purity Risk
commonAs an unregulated research peptide, actual peptide content, sequence fidelity (native vs PEG), and purity vary widely by source.
Use a tested product with a certificate of analysis.
General Mitigation Strategies
MGF/PEG-MGF is generally reported as well tolerated at community doses, with injection-site reactions being the main complaint. Rotate sites, keep doses conservative, and avoid if you have a cancer history given the shared IGF-1-family growth-promoting mechanism. The biggest practical issue is product quality. Verify source and purity.
Post Cycle Therapy (PCT)
Not hormonal. Does not affect the HPTA or testosterone. No PCT required.
How It Works
Mechanical loading shifts IGF-1 gene splicing in muscle toward the Ec (MGF) isoform within roughly 1-4 hours of damaging (eccentric) exercise, ahead of the systemic IGF-1 rise. The mature IGF-1 portion signals through the IGF-1 receptor to drive myoblast differentiation and fusion, while the separate MGF E-peptide is proposed to activate quiescent satellite cells and push them into the cell cycle (proliferation) through a receptor that appears to be distinct from IGF-1R and has not been definitively identified. The result, in the two-phase model, is that MGF kick-starts the stem-cell/proliferation phase of repair and IGF-1 handles differentiation. PEG-MGF attaches polyethylene glycol to the peptide to resist rapid clearance, allowing systemic (rather than purely local) exposure.
Fundamentals
Reference on the practices relevant to MGF (Mechano Growth Factor): how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- PEG-MGF + CJC-1295/Ipamorelin - GH secretagogue base plus local repair arm
- Native MGF post-workout + IGF-1 LR3 - Two-phase proliferation-then-differentiation idea
- MGF + BPC-157 - Recovery-focused muscle and connective-tissue repair
Legal Status
Research chemical (USA). WADA prohibited (S2 growth factors). Not FDA-approved for human use.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
MGF and PEG-MGF are prohibited at all times as growth factors under S2 (the same section that captures IGF-1 and its analogues). No TUE pathway exists for physique/performance use.
References
- Kandalla et al. 2011: MGF E-peptide activates human muscle progenitor cells (Mech Ageing Dev, PMID 21354439)
- Matheny et al. 2010: Mechano-growth factor minireview (Endocrinology, PMID 20130113)
- Fornaro et al. 2014: MGF peptide has no apparent effect on myoblasts/muscle stem cells (Am J Physiol, PMID 24253050)
- Mechano growth factor (MGF / PEG-MGF) - Wikipedia